Does prophylactic administration of somatostatin decrease the rates of complications after pancreatic resection?: A...

Area of Science:

• Gastroenterology and Hepatology
• Surgical Oncology
• Endocrinology

Background:

• Postoperative morbidity after pancreatectomy is a significant clinical concern.
• The efficacy of somatostatin in mitigating these complications is debated.
• Understanding somatostatin's effect on pancreatic function is crucial for improving surgical outcomes.

Purpose of the Study:

• To investigate the role of somatostatin in reducing postoperative complications after pancreatectomy.
• To evaluate somatostatin's influence on pancreatic cell function.
• To determine if somatostatin administration can decrease the incidence of early postoperative complications.

Main Methods:

• A randomized controlled trial involving 67 patients undergoing pancreatectomy between 2006 and 2009.
• Patients were allocated to either a somatostatin treatment group or a control group.
• Pancreatic biopsies were collected during surgery for electron microscopy and ultrastructural morphometry analysis.

Main Results:

• Overall morbidity was 35.8%.
• The treatment group experienced significantly fewer postoperative complications (17.14%) compared to the control group (56.25%; P = 0.001).
• The most frequent complication observed was pancreatic fistula (8.95%).

Conclusions:

• Perioperative intravenous somatostatin effectively inhibited exocrine pancreatic function.
• This inhibition supports a prophylactic role for somatostatin in reducing early postoperative complications after pancreatic surgery.
• The findings suggest somatostatin can be a valuable adjunct in managing patients undergoing pancreatectomy.